Emerging evidence for CHFR as a cancer biomarker

From tumor biology to precision medicine

Sarah Derks, Arjen H G Cleven, Veerle Melotte, Kim M. Smits, Johann C. Brandes, Nilofer Azad, Wim Van Criekinge, Adriaan P. De Bruïne, James G. Herman, Manon Van Engeland

Research output: Contribution to journalArticle

Abstract

Novel insights in the biology of cancer have switched the paradigm of a "one-size-fits-all" cancer treatment to an individualized biology-driven treatment approach. In recent years, a diversity of biomarkers and targeted therapies has been discovered. Although these examples accentuate the promise of personalized cancer treatment, for most cancers and cancer subgroups no biomarkers and effective targeted therapy are available. The great majority of patients still receive unselected standard therapies with no use of their individual molecular characteristics. Better knowledge about the underlying tumor biology will lead the way toward personalized cancer treatment. In this review, we summarize the evidence for a promising cancer biomarker: checkpoint with forkhead and ring finger domains (CHFR). CHFR is a mitotic checkpoint and tumor suppressor gene, which is inactivated in a diverse group of solid malignancies, mostly by promoter CpG island methylation. CHFR inactivation has shown to be an indicator of poor prognosis and sensitivity to taxane-based chemotherapy. Here we summarize the current knowledge of altered CHFR expression in cancer, the impact on tumor biology and implications for personalized cancer treatment.

Original languageEnglish (US)
Pages (from-to)161-171
Number of pages11
JournalCancer and Metastasis Reviews
Volume33
Issue number1
DOIs
StatePublished - 2014

Fingerprint

Precision Medicine
Tumor Biomarkers
Neoplasms
Therapeutics
Biomarkers
M Phase Cell Cycle Checkpoints
CpG Islands
Tumor Suppressor Genes
Methylation
Fingers

Keywords

  • CHFR promoter methylation
  • Predictive biomarker
  • Taxane sensitivity

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Medicine(all)

Cite this

Derks, S., Cleven, A. H. G., Melotte, V., Smits, K. M., Brandes, J. C., Azad, N., ... Van Engeland, M. (2014). Emerging evidence for CHFR as a cancer biomarker: From tumor biology to precision medicine. Cancer and Metastasis Reviews, 33(1), 161-171. https://doi.org/10.1007/s10555-013-9462-4

Emerging evidence for CHFR as a cancer biomarker : From tumor biology to precision medicine. / Derks, Sarah; Cleven, Arjen H G; Melotte, Veerle; Smits, Kim M.; Brandes, Johann C.; Azad, Nilofer; Van Criekinge, Wim; De Bruïne, Adriaan P.; Herman, James G.; Van Engeland, Manon.

In: Cancer and Metastasis Reviews, Vol. 33, No. 1, 2014, p. 161-171.

Research output: Contribution to journalArticle

Derks, S, Cleven, AHG, Melotte, V, Smits, KM, Brandes, JC, Azad, N, Van Criekinge, W, De Bruïne, AP, Herman, JG & Van Engeland, M 2014, 'Emerging evidence for CHFR as a cancer biomarker: From tumor biology to precision medicine', Cancer and Metastasis Reviews, vol. 33, no. 1, pp. 161-171. https://doi.org/10.1007/s10555-013-9462-4
Derks, Sarah ; Cleven, Arjen H G ; Melotte, Veerle ; Smits, Kim M. ; Brandes, Johann C. ; Azad, Nilofer ; Van Criekinge, Wim ; De Bruïne, Adriaan P. ; Herman, James G. ; Van Engeland, Manon. / Emerging evidence for CHFR as a cancer biomarker : From tumor biology to precision medicine. In: Cancer and Metastasis Reviews. 2014 ; Vol. 33, No. 1. pp. 161-171.
@article{99f0b6ef24d6423399db6ba8d6f8e135,
title = "Emerging evidence for CHFR as a cancer biomarker: From tumor biology to precision medicine",
abstract = "Novel insights in the biology of cancer have switched the paradigm of a {"}one-size-fits-all{"} cancer treatment to an individualized biology-driven treatment approach. In recent years, a diversity of biomarkers and targeted therapies has been discovered. Although these examples accentuate the promise of personalized cancer treatment, for most cancers and cancer subgroups no biomarkers and effective targeted therapy are available. The great majority of patients still receive unselected standard therapies with no use of their individual molecular characteristics. Better knowledge about the underlying tumor biology will lead the way toward personalized cancer treatment. In this review, we summarize the evidence for a promising cancer biomarker: checkpoint with forkhead and ring finger domains (CHFR). CHFR is a mitotic checkpoint and tumor suppressor gene, which is inactivated in a diverse group of solid malignancies, mostly by promoter CpG island methylation. CHFR inactivation has shown to be an indicator of poor prognosis and sensitivity to taxane-based chemotherapy. Here we summarize the current knowledge of altered CHFR expression in cancer, the impact on tumor biology and implications for personalized cancer treatment.",
keywords = "CHFR promoter methylation, Predictive biomarker, Taxane sensitivity",
author = "Sarah Derks and Cleven, {Arjen H G} and Veerle Melotte and Smits, {Kim M.} and Brandes, {Johann C.} and Nilofer Azad and {Van Criekinge}, Wim and {De Bru{\"i}ne}, {Adriaan P.} and Herman, {James G.} and {Van Engeland}, Manon",
year = "2014",
doi = "10.1007/s10555-013-9462-4",
language = "English (US)",
volume = "33",
pages = "161--171",
journal = "Cancer and Metastasis Reviews",
issn = "0167-7659",
publisher = "Springer Netherlands",
number = "1",

}

TY - JOUR

T1 - Emerging evidence for CHFR as a cancer biomarker

T2 - From tumor biology to precision medicine

AU - Derks, Sarah

AU - Cleven, Arjen H G

AU - Melotte, Veerle

AU - Smits, Kim M.

AU - Brandes, Johann C.

AU - Azad, Nilofer

AU - Van Criekinge, Wim

AU - De Bruïne, Adriaan P.

AU - Herman, James G.

AU - Van Engeland, Manon

PY - 2014

Y1 - 2014

N2 - Novel insights in the biology of cancer have switched the paradigm of a "one-size-fits-all" cancer treatment to an individualized biology-driven treatment approach. In recent years, a diversity of biomarkers and targeted therapies has been discovered. Although these examples accentuate the promise of personalized cancer treatment, for most cancers and cancer subgroups no biomarkers and effective targeted therapy are available. The great majority of patients still receive unselected standard therapies with no use of their individual molecular characteristics. Better knowledge about the underlying tumor biology will lead the way toward personalized cancer treatment. In this review, we summarize the evidence for a promising cancer biomarker: checkpoint with forkhead and ring finger domains (CHFR). CHFR is a mitotic checkpoint and tumor suppressor gene, which is inactivated in a diverse group of solid malignancies, mostly by promoter CpG island methylation. CHFR inactivation has shown to be an indicator of poor prognosis and sensitivity to taxane-based chemotherapy. Here we summarize the current knowledge of altered CHFR expression in cancer, the impact on tumor biology and implications for personalized cancer treatment.

AB - Novel insights in the biology of cancer have switched the paradigm of a "one-size-fits-all" cancer treatment to an individualized biology-driven treatment approach. In recent years, a diversity of biomarkers and targeted therapies has been discovered. Although these examples accentuate the promise of personalized cancer treatment, for most cancers and cancer subgroups no biomarkers and effective targeted therapy are available. The great majority of patients still receive unselected standard therapies with no use of their individual molecular characteristics. Better knowledge about the underlying tumor biology will lead the way toward personalized cancer treatment. In this review, we summarize the evidence for a promising cancer biomarker: checkpoint with forkhead and ring finger domains (CHFR). CHFR is a mitotic checkpoint and tumor suppressor gene, which is inactivated in a diverse group of solid malignancies, mostly by promoter CpG island methylation. CHFR inactivation has shown to be an indicator of poor prognosis and sensitivity to taxane-based chemotherapy. Here we summarize the current knowledge of altered CHFR expression in cancer, the impact on tumor biology and implications for personalized cancer treatment.

KW - CHFR promoter methylation

KW - Predictive biomarker

KW - Taxane sensitivity

UR - http://www.scopus.com/inward/record.url?scp=84899984093&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899984093&partnerID=8YFLogxK

U2 - 10.1007/s10555-013-9462-4

DO - 10.1007/s10555-013-9462-4

M3 - Article

VL - 33

SP - 161

EP - 171

JO - Cancer and Metastasis Reviews

JF - Cancer and Metastasis Reviews

SN - 0167-7659

IS - 1

ER -